Dibucaine number-994

Test info

  
Dibucaine number
  
994
  
LAB994
  
MSO
  
Dibucaine inhibition
  
Assess the presence of homozygous or heterozygous “atypical” cholinesterase variant, in patients who have low result of serum or plasma cholinesterase assay, and may be at risk of apnea when given succinylcholine muscle relaxant.
  

No single simple test currently exists that can detect all enzyme variants.

Specimen

  

Do not collect within 24 hours of administration of muscle relaxant

  
Serum
  
  
0.5 mL
  
0.2 mL
  

Immediately following collection, thoroughly mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
  
EDTA plasma
  
  

Lavender:

Immediatley following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

  

Red:

  1. Allow sample to clot
  2. Spin 
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum, within two (2) hours of sample collection

Lavender:

  1. Spin 
  2. Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as EDTA plasma, within two (2) hours of sample collection
  

Ambient (preferred) - 14 days

Refrigerated - 14 days

Frozen - 14 days

Freeze/thaw cycles - stable x3

  
  • Plasma or serum not separated from cells
  • Frozen whole blood received
  • Hemolysis

Performance

  
LabCorp Burlington (081513): R-NX
  
Su - Fr
  
3 - 5 days
  

Cholinesterase by spectrophotometry (Ellman) with dibucaine inhibition

Clinical and Interpretive info

  
Normal:            70% - 90% inhibition
Heterozygotes:  30% - 70% inhibition
Homozygotes:     0% - 30% inhibition

Billing

  
82638
  
Result 39354-6

Tracking

  
05/30/2019
  
06/13/2023
  
06/01/2023